Top Markets
Coin of the day
Regulus Therapeutics Inc. Regulus Therapeutics Inc.

Regulus Therapeutics Inc.

RGLS
Clasificación en acciones #17600
Regulus Therapeutics Inc., a biopharmaceutical firm in its clinical development... Regulus Therapeutics Inc., a biopharmaceutical firm in its clinical development phase, is dedicated to uncovering and advancing novel medications. Based in San Diego, California, the company's core focus is on modulating microRNAs to combat a variety of diseases across the United States. Its current pipeline highlights RG-012, an anti-miR compound engineered to inhibit miR-21, which is currently in a Phase II clinical study for Alport syndrome, a severe renal condition. Another significant candidate, RGLS8429, an anti-miR agent targeting miR-17, is being evaluated in a Phase 1b clinical trial for autosomal dominant polycystic kidney disease. Beyond these clinical programs, Regulus is also cultivating an extensive preclinical portfolio, emphasizing drug candidates with precise, organ-selective delivery strategies. The company was established in 2007.
Precio por acción
$8.16
Última sincronización: 2025-06-26
Capitalización bursátil
$234.57M
Cambio (1 día)
0.00%
Cambio (1 año)
0.00%
País
US
Comercio Regulus Therapeutics Inc. (RGLS)

Categoría

Historial del precio de la acción de Regulus Therapeutics Inc. (RGLS)
Precio más alto de cierre: $8.13 el 2025-06-01

Precio más bajo de cierre: $542.40 el 2012-10-01
Historial del precio de la acción de Regulus Therapeutics Inc. desde 2012 hasta 2026
Desempeño anual del precio de la acción
Año Rendimiento
2025 412.85%
2024 18.41%
2023 -5.90%
2022 -59.58%
2021 -68.07%
2020 52.53%
2019 -42.38%
2018 -88.97%
2017 -61.61%
2016 -73.01%
2015 -43.68%
2014 142.24%
2013 35.08%
2012 0.00%
Precio de la acción de empresas similares o competidoras
Empresa Precio de la acción Cambio 1a% País
$556.43 38.76%
US
$1.05K 48.60%
NL
$152.82 531.75%
US
$122.21 -10.03%
AU
$757.71 8.20%
CH